Welcome to our dedicated page for 20/20 Biolabs SEC filings (Ticker: AIDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
20/20 BioLabs filings document the company's diagnostics business, public-company registration, operating results, and capital structure. Its registration statements describe the AIDX issuer as an emerging growth company and smaller reporting company, with disclosures covering the OneTest laboratory-testing business, risk factors, securities registration, and Nasdaq listing context.
Its Form 8-K reports cover material events such as financial-results announcements and financing arrangements, including secured convertible promissory notes and warrants. The filings also provide formal records of corporate governance, securities issuance, offering-related disclosures, and other matters associated with a commercial-stage diagnostics company operating a CAP-accredited and CLIA-licensed laboratory.
20/20 Biolabs, Inc. is soliciting proxies for its 2026 virtual Annual Meeting to be held on August 18, 2026. Stockholders of record as of June 22, 2026 may vote on five proposals, including a Charter Amendment to increase authorized common stock from 50,000,000 to 500,000,000 shares and approval of a 2026 Equity Incentive Plan reserving 5,000,000 shares plus annual automatic increases equal to 7% of outstanding shares.
The proxy includes board and nominee information for six director seats, ratification of dbbmckennon as independent auditors, disclosure of audit fees for 2025 and 2024, executive compensation summaries, outstanding option schedules for named executives, and procedural voting details for virtual attendance, quorum rules and broker non-vote treatment.
20/20 Biolabs, Inc. reported that its Board of Directors approved an amendment to the company’s Amended and Restated Bylaws on May 19, 2026. The change lowers the shareholder quorum requirement for stockholder meetings from a majority of shares outstanding to one-third of shares outstanding.
This adjustment makes it easier for the company to reach a valid quorum and conduct official business at stockholder meetings, which can be important when investor participation is limited. The full text of Amendment No. 1 to the bylaws is filed as an exhibit to this report.
20/20 Biolabs, Inc. files a prospectus supplement to include its Form 10-Q and updates a resale registration for 10,105,000 shares of common stock for certain selling stockholders. The company reported cash and cash equivalents of $4,219,099, net loss of $2,174,836 for the three months ended March 31, 2026, and disclosed 5,000 shares of Series E convertible preferred stock outstanding.
The supplement references the company’s Nasdaq listing under the symbol AIDX and includes operating results showing decreased revenues to $353,375 for the quarter and working capital of $2,120,232. Management disclosed material weaknesses in internal controls and described remedial steps underway.
20/20 Biolabs, Inc. files a prospectus supplement registering 15,164,724 shares of common stock for resale by selling stockholders.
The filing incorporates the Company’s Form 10-Q for the quarter ended March 31, 2026, shows cash of $4,219,099 and a net loss of $2,174,836 for the three months then ended. Shares outstanding were 10,611,528 as of May 19, 2026.
20/20 Biolabs reported a significantly wider loss for the quarter ended March 31, 2026 as revenue declined. Revenue fell to $353,375 from $553,820, driven mainly by lower OneTest sales and continued BioCheck erosion after patent expiry.
Gross margin compressed to 17.8%, while sales, general and administrative expenses rose to $1.35 million, largely tied to Nasdaq direct listing costs. The company posted a net loss of $2.17 million, compared with $0.76 million a year earlier, and used $1.29 million in operating cash.
Liquidity improved through a private placement of series E convertible preferred stock providing $5.0 million of proceeds and $250,000 of new secured convertible notes, lifting cash to $4.22 million and working capital to $2.12 million. However, operations continue to rely on external financing, and management notes recent operating losses may persist. Material weaknesses in internal control over financial reporting remain, though remediation efforts are underway.
20/20 BioLabs reported first quarter 2026 results showing lower revenue and a wider loss but a much stronger cash position. Revenue for the three months ended March 31, 2026 was $353,375, down from $553,820 a year earlier, with gross margin at 17.8%.
Net loss widened to $2,174,836 from $764,577, reflecting higher sales, general and administrative costs tied to becoming a Nasdaq-listed public company, non-cash losses on convertible notes, and warrant remeasurement. Cash and cash equivalents increased to $4,219,099 from $1,025,987 at year-end, helped by a $5,000,000 Series E preferred stock private placement and new convertible notes.
The company highlighted state-funded firefighter cancer screening programs expected to drive revenue growth beginning in Q2 2026, a distribution agreement with Evexia Diagnostics, a CKD-focused license with ROKIT Healthcare, and the commercial launch of its OneTest™ for Longevity chronic disease risk test.
20/20 Biolabs, Inc. notified the SEC it could not file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026. The company attributes the delay to unanticipated completion delays for its financial statements and related portions of the Form 10-Q and expects to file the Form 10-Q no later than five calendar days after the prescribed due date under Rule 12b-25. The notification was signed by Chief Executive Officer Jonathan Cohen on May 15, 2026.
20/20 Biolabs, Inc. registered 15,164,724 shares of common stock for resale by certain selling stockholders. This Prospectus Supplement No. 1 amends the April 9, 2026 prospectus to include the Current Report on Form 8-K filed April 28, 2026.
The Form 8-K discloses a Global Amendment dated April 23, 2026 with Streeterville Capital that reduces the exercise price of three previously issued warrants to $2.25 per share ("subject to standard adjustments for stock splits, stock dividends, recapitalizations and similar transactions"). The Amendment permits the Company to terminate the Amendment within ninety (90) days after execution upon at least two (2) trading days' written notice, during which period Streeterville may exercise the warrants at the reduced price. The filing also notes a Nasdaq listing price used in prior transactions of $11.42 and a closing Nasdaq price on April 24, 2026 of $1.64.
20/20 Biolabs filed a Prospectus Supplement to register the resale of 10,105,000 shares of common stock by certain selling stockholders. The Supplement incorporates an April 28, 2026 Form 8-K that discloses a Global Amendment with Streeterville Capital reducing the warrants' exercise price to $2.25. The cover notes the company's Nasdaq symbol AIDX and a closing share price of $1.64 on April 24, 2026.
The 8-K summarizes prior private placements with Streeterville, including secured convertible promissory notes and multiple warrants (Warrant 1, Warrant 2, Warrant 3), a February 19, 2026 issuance of series E convertible preferred stock, and the Amendment that changes warrant economics and requires a sticker update to the registration statement. The Supplement is qualified by and should be read together with the Prospectus dated April 10, 2026.
20/20 Biolabs, Inc. entered a global amendment with Streeterville Capital on April 23, 2026 that significantly reprices existing equity warrants. The amendment reduces the exercise price of three previously issued Streeterville warrants to $2.25 per share, subject to standard anti-dilution adjustments.
These warrants were originally issued alongside secured convertible promissory notes of $295,000 and $275,000, each paired with a warrant to purchase 62,500 common shares at $8.00, and a financing in which Streeterville bought 5,000 shares of series E convertible preferred stock and a warrant to purchase 3,502,627 common shares at $11.42 per share for $5,000,000. The amendment gives the company a right to terminate within 90 days on at least two trading days’ written notice, during which period Streeterville may exercise the warrants at the reduced price.